The data clinical research organization (CRO) is also opening a third office in Hyderabad, India in the second quarter of 2017.
The facilities will offer various clinical trial services, including electronic data capture, data management, CDISC, biostatistical and SAS programming services. The Bangalore, Chennai, and Kiev offices occupy a combined space of more than 24,000 square feet.
Stephen Boccardo, Sr. VP Business Development and Commercial Strategy at Quartesian, told us the company expects to hire 100 new employees across the offices in 2017.
“There’s a lot of resources available [in India and Ukraine],” he added. “This enables us to bring people on relatively quickly as we’re growing and expanding.”
According to the company, the expansion was prompted by “tremendous” year-over-year growth.
Moving into 2017, Boccardo said the data CRO plans to double bookings from the previous year.
“We’re seeing a lot of growth and interest from several markets,” he explained, specifically in “underserved” markets such as Phase I and generics. “We’ve seen an uptick in interest there because they’re still under very tight budget restraints.”
The company has also seen growth in response to new regulations that went into effect December 2016 and require data to be submitted in a particular format.
Specifically, the requirements necessitate all datasets from studies supporting new drug applications, biologics license applications, and abbreviated new drug applications to be submitted in SEND format – Standard of Exchange of Nonclinical Data, an implementation of the CDISC Standard Data Tabulation Model (SDTM).